Veryan’s BioMimics 3D™ stent technology, intended to improve the biomechanical and blood flow characteristics of vascular stents.
Veryan has developed and patented a three dimensional (3D) stent technology based upon a helical shape that may be applied to a self-expanding stent platform. The objective of Veryan’s proprietary technology is to improve the biomechanical and flow characteristics of straight tubular stents. The focus to date has been on the arteries of the leg. Existing stents indicated for placement in the leg arteries have a straight ,tubular design that tends to straighten any curvature present in vessels. This straightening effect may interfere with normal shortening of the femoropopliteal artery during lower limb movement, such as when the knee is bent. In addition, fracture of Nitinol stents has been reported in the femoropopliteal application. The inherent shortcomings of exisiting straight tubular stents are driving Veryan’s development of BioMimics 3D™ technology.
Veryan has applied this 3D technology to its proprietary stent platform to create the BioMimics 3D self-expanding Nitinol stent (see image) for use in the treatment of patients with peripheral arterial disease requiring endovascular intervention to relieve obstruction or occlusion of the femoropopliteal artery. The design of the BioMimics 3D stent is built on the principles underlying the latest generation of Nitinol stent technology - adequate mechanical radial support and plaque coverage, good flexibility, durability against fracture, clear visualisation and delivery accuracy - with the addition of the biomechanical and flow characteristics arising from the 3D geometry.
Veryan has acheived CE Mark approval for the BioMimics 3D stent and is currently completing 2-year patient follow up from this initial trial.
The research behind Veryan's technology was originally carried out by Professor Colin Caro at Imperial College London.
Veryan’s BioMimics 3D stent is initially targeted at the market for peripheral stents, which exceeds £1 billion per year with a 20% CAGR due to the emergence of new technology and expanding indications for vascular stents.
Veryan has raised total funding to date of £18.6m in equity and loan stock, from investors Oxford Capital Partners, Seroba Kernel Life Sciences and NESTA, alongside Imperial Innovations
Two-year follow-up data shows that Veryan's helical geometry BioMimics 3D stent provides improvement in long-term patency when compared to straight nitinol stentRead more
Veryan receives CE Mark for its BioMimics 3D stentRead more
Completed enrolment of patients for its BioMimics 3D trial
Announced the appointment of medical device industry veterans Todd M. Pope and Jeffrey B. Jump as Non-executive directors
Appointment of Nick Yeo, formerly of Light Sciences, Inc., as Chief Operating Officer.
Raised £5m in a round co-led by Innovations and Seroba Kernel Life Sciences.